Deals In Depth: October 2021
Executive Summary
Six $1bn+ alliances were penned in October. Topping the list was a potential $3.6bn deal between Poseida Therapeutics and Takeda to utilize Poseida's genetic engineering platforms for the research and development of up to eight gene therapies. The collaboration will focus on non-viral in vivo gene therapy programs, including Poseida's preclinical hemophilia A program P-FVIII-101. Poseida will lead research activities up to candidate selection, after which Takeda will assume responsibility for further exclusive global development and commercialization.
You may also be interested in...
Deals In Depth: April 2022
In the top April alliance by deal value, Jazz Pharmaceuticals acquired exclusive global development and commercialization rights to Werewolf Therapeutics' WTX-613. Preclinical WTX-613 is an engineered IFN⍺2b cytokine pro-drug that is activated specifically within the tumor microenvironment where it can stimulate IFNα receptors on cancer-fighting immune effector cells. Jazz expects to submit an IND application to the FDA for WTX-613 in 2023. Jazz paid $15M up front and Werewolf is eligible to receive development, regulatory and commercial milestone payments of up to $1.26bn, plus royalties.
Dealmaking Quarterly Statistics, Q1 2022
During Q1, biopharma merger and acquisition value reached $9.9bn and drew in $51.2bn in potential deal value from alliances. Device company M&A values reached $4.6bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $52.5m.
Financing Quarterly Statistics, Q1 2022
During Q1, biopharmas brought in an aggregate $17.9bn in financing and device company fundraising totaled $2.2bn; while in vitro diagnostic firms and research tools players raised $1.5bn.